Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

滑膜肉瘤 医学 粘液样脂肪肉瘤 内科学 队列 人口 肉瘤 脂肪肉瘤 外科 临床终点 肿瘤科 软组织肉瘤 细胞减少 病理 临床试验 骨髓 环境卫生
作者
Sandra P. D’Angelo,Dejka M. Araujo,Albiruni R. Abdul Razak,Mark Agulnik,Steven Attia,Jean‐Yves Blay,Irene Carrasco García,John A. Charlson,Edwin Choy,George D. Demetri,Mihaela Druta,Édouard Forcade,Kristen Nooshin Ganjoo,John W. Glod,Vicki Leigh Keedy,Axel Le Cesne,David A. Liebner,Víctor Moreno,Seth M. Pollack,Scott M. Schuetze
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10435): 1460-1471 被引量:363
标识
DOI:10.1016/s0140-6736(24)00319-2
摘要

Summary

Background

Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for the treatment of patients with HLA-A*02 and MAGE-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma.

Methods

SPEARHEAD-1 was an open-label, non-randomised, phase 2 trial done across 23 sites in Canada, the USA, and Europe. The trial included three cohorts, of which the main investigational cohort (cohort 1) is reported here. Cohort 1 included patients with HLA-A*02, aged 16–75 years, with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (confirmed by cytogenetics) expressing MAGE-A4, and who had received at least one previous line of anthracycline-containing or ifosfamide-containing chemotherapy. Patients received a single intravenous dose of afami-cel (transduced dose range 1·0 × 109–10·0 × 109 T cells) after lymphodepletion. The primary endpoint was overall response rate in cohort 1, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumours (version 1.1) in the modified intention-to-treat population (all patients who received afami-cel). Adverse events, including those of special interest (cytokine release syndrome, prolonged cytopenia, and neurotoxicity), were monitored and are reported for the modified intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT04044768; recruitment is closed and follow-up is ongoing for cohorts 1 and 2, and recruitment is open for cohort 3.

Findings

Between Dec 17, 2019, and July 27, 2021, 52 patients with cytogenetically confirmed synovial sarcoma (n=44) and myxoid round cell liposarcoma (n=8) were enrolled and received afami-cel in cohort 1. Patients were heavily pre-treated (median three [IQR two to four] previous lines of systemic therapy). Median follow-up time was 32·6 months (IQR 29·4–36·1). Overall response rate was 37% (19 of 52; 95% CI 24–51) overall, 39% (17 of 44; 24–55) for patients with synovial sarcoma, and 25% (two of eight; 3–65) for patients with myxoid round cell liposarcoma. Cytokine release syndrome occurred in 37 (71%) of 52 of patients (one grade 3 event). Cytopenias were the most common grade 3 or worse adverse events (lymphopenia in 50 [96%], neutropenia 44 [85%], leukopenia 42 [81%] of 52 patients). No treatment-related deaths occurred.

Interpretation

Afami-cel treatment resulted in durable responses in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. This study shows that T-cell receptor therapy can be used to effectively target solid tumours and provides rationale to expand this approach to other solid malignancies.

Funding

Adaptimmune.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage的应助被ysy采纳,获得10
刚刚
花花完成签到,获得积分10
1秒前
1秒前
小马过河发布了新的文献求助10
1秒前
1秒前
mercurial发布了新的文献求助10
1秒前
你别管完成签到,获得积分10
1秒前
Xiaoab发布了新的文献求助10
1秒前
1秒前
2秒前
搜集达人的应助被L雨采纳,获得10
2秒前
2秒前
大壮完成签到 ,获得积分10
2秒前
夏虫完成签到,获得积分10
3秒前
华仔的应助被zhou采纳,获得10
4秒前
Galaxy发布了新的文献求助50
4秒前
风吹麦浪的应助被怡然的海瑶采纳,获得10
4秒前
深情安青的应助被lyn采纳,获得10
4秒前
LamuQili完成签到,获得积分10
4秒前
MrZ1完成签到,获得积分10
5秒前
5秒前
amm完成签到,获得积分10
5秒前
丘比特的应助被李志采纳,获得10
5秒前
111发布了新的文献求助10
6秒前
6秒前
李进步完成签到,获得积分10
6秒前
丘比特的应助被kai采纳,获得10
6秒前
友好远望发布了新的文献求助10
6秒前
6秒前
7秒前
Ck完成签到,获得积分10
7秒前
爆米花的应助被钱百万采纳,获得10
7秒前
7秒前
7秒前
aaaa完成签到,获得积分10
7秒前
胖子完成签到,获得积分10
8秒前
xm发布了新的文献求助10
8秒前
SZA发布了新的文献求助10
8秒前
8秒前
华仔的应助被迈巴贺采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162244
求助须知:如何正确求助?哪些是违规求助? 9556607
关于积分的说明 21735793
捐赠科研通 7752519
什么是DOI,文献DOI怎么找? 3427674
关于科研通互助平台的介绍 2552678
邀请新用户注册赠送积分活动 2472271